Else Nutrition: Canaccord Cuts Target To $2.00 After Financing

On June 22, Else Nutrition (TSX: BABY) announced that it raised $7.29 million by selling 6,940,000 units at a price of $1.05 per unit. Each unit is comprised of one common share and one warrant, exercisable at $1.25, and is valid for 60 months.

Else Nutrition says that this capital will be used “to fund research and development including clinical studies, fund sales and marketing, acquire inventory, establish a manufacturing facility, and for general corporate purposes.”

In Canaccord Genuity’s note on the financing, they reiterate their speculative buy rating but slash their 12-month price target to C$2.00 from C$2.50, saying that they estimated the net proceeds from this raise to be $6.6 million after backing out 7% in broker commission and roughly $0.25 million in offering expenses.

Cambria Gold Mines — sponsored Sponsored · Cambria Gold Mines

Else notes that of this $6.6 million, $2.4 million will go to sales and marketing initiatives, $2.0 million will go to R&D, $1.3 million will go to the acquisition of 3-6 months worth of inventory and the last $0.9 million will go to general corporate and working capital purposes.

Else Nutrition also announced that it will be entering the Canadian market next month with a plan to launch all three of its U.S product lines in Canada. Canaccord says that this news does not even impact their near-term estimates, but they “view this as a positive development, reaffirming BABY’s focus on international expansion.” As the company can use these products to create, “a foundation on which BABY can establish brand recognition.”

Prior to this raise, Canaccord expected Else Nutrition to do a single $40 million raised during the fourth quarter of this year. Now they forecast that the company does two $30 million equity raises, one in the fourth quarter of 2023 and one in the fourth quarter of 2024.

Below you can see Canaccord’s updated estimates.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to the organizations discussed. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Inside a Forgotten High-Grade Gold Mine in the Yukon | Blue Jay Gold [DD-on-the-GO Ep. 10]

WHICH MINING STOCKS CAN STILL RUN? | Mining Stock Mailbag [Nov. 9-13]

Silver’s Bull Market Isn’t Over | Peter Krauth

Recommended

Epic Gold Delivers Maiden 279,000 Ounce Inferred Resource at Wilson Project

First Phosphate Adds UK Export Finance to Growing Export Credit Lineup With C$220 Million Letter of Interest

Related News

Stifel Downgrades Aurora Cannabis Price Target To $3.60 Based On Liquidation Analysis

This morning, Stifel downgraded their 12-month price target on Aurora Cannabis (TSX: ACB) (NYSE: ACB)...

Wednesday, October 28, 2020, 10:59:00 AM

Tyson Foods: BMO Lifts Price Target To $115 After Strong Q1 Results

On February 7th, Tyson Foods (NYSE: TSN) reported their fiscal first quarter results for the...

Thursday, February 10, 2022, 02:44:00 PM

BMO Expects Copper Production To Continue To Grow At Ivanhoe Mines

Ivanhoe Mines (TSX: IVN) earlier this week reported its quarterly production of copper. The company...

Friday, July 8, 2022, 02:21:00 PM

Xebec Adsorption: Canaccord Gets Bullish On Company, Lifts Price Target

On April 12th, Xebec Adsorption (TSX: XBC) announced that it received a US$113.5 million order...

Saturday, April 16, 2022, 11:17:00 AM

Organigram: Analysts Upgrade Targets Following BAT Investment

On March 9th, Organigram Holdings (TSX: OGI) (NASDAQ: OGI) announced that they received a C$221...

Sunday, March 14, 2021, 06:32:00 PM